Oral Silica Nanoparticles Lack of Neurotoxic Effects in a Parkinson’s Disease Model: a Possible Nanocarrier?

Oral Silica Nanoparticles Lack of Neurotoxic Effects in a Parkinson’s Disease Model: a Possible Nanocarrier?

Publication date: Aug 08, 2019

Silica nanoparticles (SiO2-NP) are an option as drug carriers due to their biodegradability, biocompatibility, and capacity to bind themselves to other compounds. However, until now, the effect of these particles on the brain when neurodegeneration occurs is unknown. Hence, this work focused on the in vivo evaluation of the neurotoxic effects of SiO2-NP when oxidative and inflammation are present during the development of Parkinson’s disease. To determine whether SiO2-NP may act as a non-neurotoxic carrier we evaluated if the intragastric administration (ig) of SiO2-NP of 150 nm (25, 50 and 100 mg/kg administered for five consecutive days) increased neuronal damage induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. SiO2-NP administration did not further decrease cell viability assessed by MTT reduction, nor increased lipid peroxidation measured by TBARS or TNFα levels in the striatum and the substantia nigra in the MPTP model. Furthermore, we observed no additional reduction in striatal dopamine levels. The present results suggest that SiO2-NP of 150 nm are suitable nanocarrier for Parkinson’s disease drugs without generating any additional damage.

Guzman-Ruiz, M.A., de la Mora, M.B., Torres, X., Meza, C., Garcia, E., and Chavarria, A. Oral Silica Nanoparticles Lack of Neurotoxic Effects in a Parkinson’s Disease Model: a Possible Nanocarrier? 21894. 2019 IEEE Trans Nanobioscience.

Concepts Keywords
Biocompatibility TBARS
Biodegradability Olney’s lesions
Brain Substantia nigra
Dopamine Silicon dioxide
IEEE MPTP
Inflammation Excipients
Lipid Peroxidation Materials
Methyl Neurotoxins
MPTP Drug carriers
Nanoparticles Chemical substances
Neurodegeneration Chemical compounds
Neurotoxic Non neurotoxic carrier
NP
Parkinson
Phenyl
Silica
SiO2
Striatal
Striatum
Substantia Nigra
TBARS
TNF
Vivo

Semantics

Type Source Name
drug DRUGBANK Dopamine
gene UNIPROT TNF
gene UNIPROT MAGEE1
disease MESH development
disease MESH inflammation
drug DRUGBANK Silicon dioxide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *